140 related articles for article (PubMed ID: 31787704)
1. Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol.
Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Miyata Y; Miyazawa Y; Saito A; Iwasaki H
Kurume Med J; 2020 Jul; 66(1):37-42. PubMed ID: 31787704
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
5. [Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):448-51. PubMed ID: 27151008
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients.
Yamasaki S; Kada A; Choi I; Iida H; Sekiguchi N; Harada N; Sawamura M; Shimomura T; Komeno T; Yano T; Yoshida I; Yoshida S; Sunami K; Hishita T; Takatsuki H; Ohshima K; Takeshita M; Saito AM; Iwasaki H; Nagai H
EJHaem; 2020 Nov; 1(2):507-516. PubMed ID: 35844987
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Sirohi B; Cunningham D; Norman A; Last K; Chau I; Horwich A; Oates J; Chong G; Wotherspoon A
Hematology; 2007 Apr; 12(2):149-53. PubMed ID: 17454196
[TBL] [Abstract][Full Text] [Related]
9. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
10. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Barton S; Hawkes EA; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Attygalle A; Horwich A; Potter M; Ethell M; Dearden C; Gleeson M; Chau I
Eur J Haematol; 2015 Mar; 94(3):219-26. PubMed ID: 25039915
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone).
Naka R; Tada K; Kaneko H; Nagata O; Tashima M; Mizutani C; Imada K
Leuk Lymphoma; 2022 Jun; 63(6):1508-1511. PubMed ID: 35105261
[No Abstract] [Full Text] [Related]
16. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
Witzens-Harig M; Memmer ML; Dreyling M; Hess G
BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
[TBL] [Abstract][Full Text] [Related]
17. [Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
Aota Y; Tanaka M; Watanabe N; Tomomatu J; Gotoh A; Komatu N
Gan To Kagaku Ryoho; 2015 Jan; 42(1):51-5. PubMed ID: 25596679
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
